Effect of Race on Left Ventricular Ejection Fraction Decline After Initial Improvement with Beta Blockers in Patients with Non-Ischemic Cardiomyopathy: A Retrospective Analysis

Iosif Kelesidis · Patrick Hourani · Christopher Varughese · Ronald Zolty

Published online: 15 August 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract

Background Although beta blockers (BBs) are established therapy in heart failure, some patients whose left ventricular ejection fraction (LVEF) initially increases on BB therapy experience a subsequent LVEF decline. This study aimed to evaluate the proportion of patients with non-ischemic cardiomyopathy (NICM) whose LVEF declines while on BB therapy and determine important predictors of LVEF decline.

Methods A retrospective analysis of 238 patients receiving a BB (carvedilol, metoprolol succinate, or tartrate), with an ejection fraction of ≤40% and NICM, whose LVEF initially rose ≥5% after 1 year of BB therapy, was conducted. Post-response LVEF decline ≥5 % to a final LVEF of ≤35 % was evaluated within 4 years of BB initiation.

Results In our study, we had 52 Caucasians (22%), 78 Hispanics (33%), and 108 African Americans (45%). Overall, 32 patients (13.44%) had post-response LVEF decline. The nadir LVEF of patients with post-response LVEF decline was 25% (interquartile range 20–27). Compared with others, Hispanics had lower nadir LVEF (22%, p < 0.001). Important predictors of LVEF decline were Hispanic race (odds ratio (OR) 6.094, p < 0.001), New York Heart Association (NYHA) class (OR 2.287, p < 0.05), baseline LVEF (OR 1.075, p < 0.05), and age (OR 0.933, p < 0.001).

Conclusion A significant proportion (13.44%) of NICM patients with LVEF increase over 1 year of BB therapy experienced subsequent LVEF decline. Race, NYHA class, baseline LVEF, and age are important predictors of this decline.

1 Introduction

Heart failure (HF) is a major public health problem [1–3] with poor outcomes especially in African Americans (AA) and Hispanics [1, 4]. The higher mortality in these groups has been attributed to differences in the severity and causes of HF, the prevalence of coexisting conditions and risk factors [2], socioeconomic and cultural factors, and access to high-quality medical care [5].

Beta blockers (BBs) are beneficial in patients with symptomatic HF or left ventricular (LV) systolic dysfunction [6–8]. The increase in left ventricular ejection fraction (LVEF) is greater in patients with lower baseline LVEF after treatment with BB therapy [9, 10]. It has been suggested that after response to BB therapy, the BB should not be withdrawn, because of an increased risk of clinical deterioration or death from progressive congestive heart failure (CHF) [11].

However, response to BBs may vary among different ethnic groups [12–14]. There may be race-related genetic differences in the beta-adrenergic pathway explaining that difference. Differences such as the frequency of the G-protein-coupled receptor kinase (GRK)-Leu41 polymorphism, which desensitizes beta-adrenergic receptors, have been found between AA and Caucasian patients [15]. Overall, BBs have been shown to have similar benefits in both AA and Caucasians [16–20]. Previous HF studies
have generally been limited to comparisons between AA and Caucasian populations [2, 12], but there are few comparative statistics concerning HF in Hispanics, one of the fastest-growing segments of the US population [21].

For patients who experience an improvement in ventricular performance on BB therapy, there is little data regarding whether this improved performance is maintained on continued BB therapy. Although several studies have shown improvements in mortality and hospitalizations for CHF over more than 2 years, there is little data following LVEF on BB therapy past 1 year [7, 8, 17, 19, 22, 23]. Of special interest is the effect of BBs on non-ischemic cardiomyopathy (NICM) since the effect of BBs on LVEF is often unpredictable in this group [7, 24]. Therefore, it is unknown with what frequency LVEF increase on BB therapy is maintained past 1 year in patients with HF. Moreover, while substantial information is available on racial differences in mortality and risk factors, much less is known about racial differences in LVEF response to BBs in patients with NICM.

This study aimed to examine the frequency of decline in LVEF after initial response to BB therapy in patients with NICM and to compare this frequency between AA, Hispanic, and Caucasian patients.

2 Methods

2.1 Study Population

A total of 238 patients with baseline a left ventricular ejection fraction (LVEF) of ≤40 % utilizing BBs (carvedilol, metoprolol succinate, or tartrate) with NICM who were followed at the HF clinic of Weiler Hospital of the Albert Einstein College of Medicine were analyzed retrospectively. Patients with ischemic and hypertrophic cardiomyopathy, hemodynamically significant valvular lesions, severe bronchospastic lung disease, baseline heart rate (HR) <60/min or systolic blood pressure (BP) <90 mmHg were excluded. Patients whose LVEF failed to rise by ≥5 % after 1 year of BB therapy were also excluded.

2.2 Study Design

The clinical design was a retrospective study aimed at analyzing the effects of BBs on LVEF response among a multi-ethnic population. Approval was granted from the Albert Einstein College of Medicine Institutional Review Board. BBs were titrated up to the maximum tolerable dose without a predefined time schedule. The maximum tolerable dose was the daily dose over which there was either (1) aggravation of dyspnea or edema, (2) systolic BP <90 mmHg or HR <60/min at rest, or (3) a need to increase the concomitant medication for HF. The assignment of race was by self-report. LVEF was measured using 2-dimensional echocardiography and the modified Simpson’s rule. The following measurements were taken: LVEF before BB therapy, LVEF after 1 year of BB therapy, and subsequent LVEF measurements while still on BB therapy after 1 year. As in previous studies [8, 25], LVEF responders to beta blockade were defined as patients with an absolute increase in LVEF ≥5 % after maximal doses of BB. The lowest LVEF at any time subsequent to the LVEF measurement at 1 year was noted. If the lowest subsequent LVEF was ≤35 % and was at least 5 % lower than LVEF at the end of the first year of BB therapy, the term ‘post-response LVEF decline’ was assigned. A high dose of BB was defined similarly to prior studies [6–8]. For example, a high dose of metoprolol was defined as ≥150 mg oral (PO) daily, whereas a high dose of carvedilol was defined as ≥50 mg PO daily.

2.3 Statistical Analyses

Statistical analyses were performed using STATA version 12.0 statistical software. A p value of ≤0.05 was considered statistically significant. Continuous data are presented as median and interquartile range in variables that were not normally distributed, while categorical data are presented as number (percentage of patients). Comparisons between groups were made using two-sample t test, one-way ANOVA or the non-parametric equivalent for continuous variables and Chi-square test or Fisher’s exact test for categorical data. Pearson and Spearman correlation coefficients (r) were used to quantify associations between variables. The effects of beta blockade on LVEF change after 1 year were compared using paired t test or the non-parametric equivalent. To determine important predictors of post-response LVEF decline, we also performed multi-variable logistic regression analysis.

3 Results

3.1 Clinical Characteristics

This study included 238 patients: 78 Hispanics, 108 AA, and 52 Caucasians. The clinical characteristics of the study cohort stratified by LVEF response are displayed in Table 1. Overall, the median age was 62 years. As shown, patients with post-response LVEF decline were predominantly Hispanics (44 vs. 29 %, p < 0.01), and more often had intra-cardiac defibrillator (ICD) (56 vs. 27 %, p < 0.001) compared with patients with sustained LVEF response.

Regarding medication use (Table 2), 142 patients (60 %) received carvedilol, whereas 96 patients (40 %) received metoprolol. The median dose of carvedilol was 25 mg daily,
whereas the median dose of metoprolol was 88 mg daily. As shown, compared with patients with sustained LVEF response, patients with post-response LVEF decline were on lower doses of carvedilol (25 vs. 37.5 %, \( p < 0.01 \)) but not metoprolol. Regarding overall dose of BB (combined), there was no difference between the different LVEF response groups (higher vs. lower dose). Most of the patients (95 %) were on an angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB).

### 3.2 Left Ventricular Ejection Fraction (LVEF) Improvement After Beta Blockade

Among 238 patients with NICM, 32 (13 %) had post-response LVEF decline and 206 (87 %) had sustained LVEF response. Overall, there was a significant improvement of LVEF from baseline after 1 year of BB (30–44 %, \( p < 0.001 \)). Figure 1 shows change in LVEF after BB in patients with NICM within 4 years after the initial LVEF. There was no difference in the LVEF before initiation of BB in the two LVEF response groups (30 vs. 29 %, \( p = 0.098 \)). Compared with patients with post-response LVEF decline, patients with sustained LVEF response had a higher LVEF at 1 year (47 vs. 41 %, \( p < 0.01 \)) and a higher nadir of LVEF (40 vs. 25 %, \( p < 0.001 \)).

Table 3 shows differences in change in LVEF between different races. Compared with other races, Hispanics had lower LVEF increase after 1 year of BB (40 %, \( p < 0.01 \)) and lower nadir LVEF in both the post-response LVEF decline group (22 %, \( p < 0.001 \)) and sustained LVEF response group (32 %, \( p < 0.01 \)) (Fig. 2). There was no difference in the percentage of sustained and post-response LVEF decline between races.

### 3.3 Predictors of Post-Response LVEF Decline

Table 4 shows results of the multivariable logistic analysis using post-response LVEF decline as the outcome of interest. Hispanic race was a significant predictor of LVEF decline in both unadjusted (odds ratio (OR) = 3.128, \( p < 0.01 \)) and adjusted analyses (OR 6.094, \( p < 0.001 \)). Age (OR 0.933, \( p < 0.001 \)) and baseline LVEF (OR 1.075, \( p < 0.05 \)) also remained significant predictors of post-response LVEF decline. Gender, New York Heart Association (NYHA) class, use of an ACEI/ARB, and dose of BB were not significant predictors of LVEF decline. Similar results were noted when we examined the post-response LVEF decline at 1 year (data not shown).

### 4 Discussion

This study aimed to examine the frequency of decline in LVEF after initial response to BB therapy and to compare this frequency between AA, Hispanic, and Caucasian patients. The primary finding of this study was that there might be a significant proportion of HF patients whose LVEF declines after initially responding to BB therapy. This conclusion is drawn from the observed occurrence of LVEF decline after initial response to BB therapy at a rate of 13.44 % over 4 years after the initiation of therapy. Compared with other races, Hispanics had lower nadir LVEF (22 %, \( p < 0.001 \)). Important predictors of LVEF decline were Hispanic race, NYHA class, baseline LVEF, and age, but not gender.

In our study, we found that there seems to exist an occurrence of LVEF decline after initial response to BB therapy at a rate of 13.44 % over 4 years after the initiation of therapy in patients with NICM. Prior studies have shown

\[ \Delta \text{Adis} \]
that patients with NICM may respond better to BBs than patients with ischemic cardiomyopathy [26–28]. Patients with NICM have initially increased wall tension due to dilated LV that causes increased myocardial oxygen demands. The global subendocardial ischemia might form a homogeneous substrate for BB action. Therefore BBs may find a more homogeneous substrate in the first months after initiation of therapy. During therapy and maybe over time because of changes in wall stress, this substrate may change and the effect of BBs in LVEF declines. Another factor that may explain the percentage of post-response LVEF decline in patients with NICM may be genetic variability. Prior studies have shown that patients with certain beta receptor genotypes were associated with better clinical response to BBs compared with others [15, 29–32]. Perhaps the patients with post-response LVEF decline have different polymorphisms than the patients with sustained LVEF response. Future research aimed at analyzing polymorphisms among patients with NICM who do not seem to have a sustained response to BBs may yield interesting results.

Interestingly, we found that Hispanics with chronic HF had worse LVEF response and post-response LVEF decline after use of a BB compared with other races. To our knowledge this is one of the first studies to examine differences in LVEF response between AA and Hispanics with NICM. Although the Hispanic population has been shown to comprise a high-risk cardiovascular group [33–

### Table 2

| Medications                                      | All NICM responders after 1 year of BB (N = 238) | Post-response LVEF decline (n = 32) | Sustained LVEF response (n = 206) | p value |
|-------------------------------------------------|-------------------------------------------------|------------------------------------|-----------------------------------|---------|
| Carvedilol                                      | 142 (60 %)                                      | 24 (75 %)                          | 118 (57 %)                        | 0.06    |
| Median-dose carvedilol (mg) (range of dose)     | 25 (18.75–50)                                   | 25 (12.5–25)                       | 37.5 (25–50)                      | 0.020   |
| Low-dose carvedilol (6.25 mg PO bid) (n, %)     | 35 (15 %)                                       | 9 (28 %)                           | 26 (13 %)                         | 0.021   |
| Medium-dose carvedilol (12.5 mg PO bid)         | 49 (21 %)                                       | 11 (34 %)                          | 38 (18 %)                         | 0.038   |
| High-dose carvedilol (25 mg PO bid)             | 58 (24 %)                                       | 4 (13 %)                           | 54 (26 %)                         | 0.093   |
| Metoprolol                                      | 96 (40 %)                                       | 8 (25 %)                           | 88 (43 %)                         | 0.06    |
| Median-dose metoprolol (mg)                     | 87.5 (50–100)                                   | 75 (37.5–150)                      | 87.5 (50–100)                     | 0.811   |
| Low-dose metoprolol (25 mg PO bid)              | 48 (20 %)                                       | 4 (13 %)                           | 44 (21 %)                         | 0.245   |
| Medium-dose metoprolol (50 mg PO bid)           | 27 (11 %)                                       | 2 (6 %)                            | 25 (12 %)                         | 0.329   |
| High-dose metoprolol (>75 mg PO bid)            | 21 (9 %)                                        | 2 (6 %)                            | 19 (9 %)                          | 0.581   |
| Overall dose of BB (combined)                   |                                                |                                    |                                   |         |
| Low                                             | 83 (35 %)                                       | 13 (41 %)                          | 70 (34 %)                         | 0.463   |
| Medium                                          | 76 (32 %)                                       | 13 (41 %)                          | 63 (31 %)                         | 0.257   |
| High                                            | 79 (33 %)                                       | 6 (19 %)                           | 73 (35 %)                         | 0.062   |
| ACEI or ARB                                      | 226 (95 %)                                      | 30 (94 %)                          | 196 (95 %)                        | 0.737   |
| Hydralazine                                     | 40 (17 %)                                       | 2 (6 %)                            | 38 (18 %)                         | 0.086   |
| Nitrates                                        | 32 (13 %)                                       | 0 (0 %)                            | 32 (16 %)                         | 0.017   |
| Spironolactone                                   | 134 (56 %)                                      | 22 (69 %)                          | 112 (54 %)                        | 0.127   |
| Digoxin                                         | 120 (50 %)                                      | 14 (44 %)                          | 106 (51 %)                        | 0.417   |
| Calcium channel blocker                          | 42 (18 %)                                       | 4 (13 %)                           | 38 (18 %)                         | 0.412   |

p value (Chi-square for categorical variables and Mann–Whitney test for continuous variables) for comparison between groups (post-response LVEF decline vs. sustained LVEF response)

ACEI Angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, BB beta blocker, bid twice daily, LVEF left ventricular ejection fraction, NICM non-ischemic cardiomyopathy, PO oral

Fig. 1 Change in LVEF after BB in patients with NICM. Compared with patients with post-response LVEF decline, patients with sustained LVEF response had higher LVEF at 1 year (47 vs. 41 %, p < 0.01) and higher nadir of LVEF (40 vs. 25 %, p < 0.001). BB beta blocker, LVEF left ventricular ejection fraction, NICM non-ischemic cardiomyopathy

△ Adis
there are very limited data on Hispanic patients with chronic systolic HF. AA have been underrepresented in major HF trials, whereas Hispanic patients have been nearly absent in most clinical trials, and thus there are very limited data regarding the effect of medications such as BBs in this ethnic group. Although LVEF patterns in Hispanic subgroups compared with non-Hispanic whites have been examined in the MESA (Multi-Ethnic Study of Atherosclerosis) [34, 35], these patterns have not been associated with use of BBs. In our study, we confirm prior findings that Hispanics have differences in clinical response of HF parameters compared with other races [36]. Finally, we extended this finding by showing that Hispanics have worse LVEF response and post-response LVEF decline compared with other races after use of BBs.

The different LVEF response to BBs among races can be explained by a few factors [12–14]. A difference in LVEF response and LVEF decline can be explained by differences among ethnic groups with respect to ancestry/race [37], socioeconomic factors [5], and dietary and lifestyle risk factors for cardiovascular disease [38]. However, our study was not designed to explain why LVEF response and LVEF decline seems to differ in different ethnic subgroups and socioeconomic status was not one of the predictors of LVEF decline. Similar to other studies [17–20], we found that AA and Caucasians had similar response to BBs after 1 year and similar post-response LVEF decline. However, other studies such as the beta-blocker evaluation of survival trial (BEST) showed that AA patients had a worse HF prognosis than Caucasians because of genetic differences [20]. A genetic substudy of the BEST data, which evaluated the effects of BBs among differing B-gene polymorphisms.

### Table 3 Differences in change in LVEF between different races (patients with post-response LVEF decline and patients with sustained LVEF response)

|                        | All NICM (N = 238) | Caucasians (n = 52) | Hispanics (n = 78) | AA (n = 108) | p Value |
|------------------------|--------------------|----------------------|--------------------|--------------|---------|
| Post-response LVEF decline [n (%)] | 32 (6 (19)) | 14 (44)) | 12 (38) | 0.288 |
| Baseline LVEF before BB [median (IQR)] | 30 (24–35) | 34 (24–42) | 32 (22–36) | 27 (19–31) | 0.024 |
| LVEF after 1 year of BB [median (IQR)] | 47 (35–50) | 40 (30–48) | 45 (36–52) | <0.01 |
| Post-response nadir LVEF [median (IQR)] | 27 (20–31) | 22 (20–25) | 26 (24–32) | <0.01 |
| Sustained LVEF response [n (%)] | 206 | 47 (23) | 60 (29) | 99 (48) | 0.147 |
| Baseline LVEF before BB [median (IQR)] | 29 (23–36) | 27 (22–30) | 30 (20–38) | 30 (25–35) | 0.036 |
| LVEF after 1 year of BB [median (IQR)] | 47 (35–54) | 49 (38–55) | 38 (22–41) | 44 (34–48) | <0.01 |
| Post-response nadir LVEF [median (IQR)] | 40 (25–44) | 42 (31–46) | 32 (25–37) | 36 (28–40) | 0.005 |

p value for comparison of different races

AA African Americans, BB beta blocker, IQR interquartile range, LVEF left ventricular ejection fraction, NICM non-ischemic cardiomyopathy

### Table 4 Important predictors of post-response LVEF decline (multivariable logistic regression). Final models adjusted for important clinical characteristics such as age, gender, NYHA class

| Predictors | Post-response LVEF decline (n = 32) |
|------------|-----------------------------------|
|            | Unadjusted | Adjusted |
|            | OR         | p value | OR         | p value |
| Baseline LVEF (overall) | 1.047 | 0.038 | 1.075 | 0.029 |
| Race (white is reference) | | | | |
| Hispanic race | 3.128 | 0.003 | 6.094 | <0.001 |
| AA | 0.926 | 0.842 | 0.595 | 0.224 |
| NYHA class | 1.431 | 0.240 | 2.287 | 0.035 |
| BB dose (low dose of BB is reference) | | | | |
| Medium-dose BB | 1.553 | 0.259 | 1.220 | 0.687 |
| High-dose BB | 0.420 | 0.069 | 0.312 | 0.063 |
| ACEI/ARB | 0.765 | 0.738 | 0.532 | 0.472 |
| Gender | 0.652 | 0.265 | 0.951 | 0.910 |
| Age | 0.960 | 0.005 | 0.933 | <0.001 |

AA African Americans, ACEI angiotensin-converting enzyme inhibitors, ARB Angiotensin II receptor blockers, BB beta blocker, LVEF left ventricular ejection fraction, NYHA New York Heart Association, OR odds ratio

**Fig. 2** Change in LVEF after BB in patients with NICM. Compared with other races, Hisp had a lower LVEF increase after 1 year of BB (p < 0.01) and lower nadir LVEF in both the post-response LVEF decline group (22 %, p < 0.01) and sustained LVEF response group (32 %, p < 0.01). AA African Americans, BB beta blocker, Cauc Caucasians, Hisp Hispanics, LVEF left ventricular ejection fraction, NICM non-ischemic cardiomyopathy
showed that patients with certain beta receptor genotypes were associated with the better clinical response to BBs compared with others [15, 29–32]. Another study showed that carvedilol significantly increased LVEF in CHF patients with the Glu(27)beta(2)-adrenergic receptor allele [39]. Therefore differences in LVEF response to BBs [40, 41] could be attributed to genetic differences. Hispanic patients with NICM may have genetic polymorphisms that could explain why this racial group may be more susceptible to post-response LVEF decline compared with other races. In this regard, the interactions between Hispanic race, care-seeking behavior, and access to high-quality HF care remain important areas for future investigation, and future research aimed at analyzing polymorphisms among Hispanics and AA may yield interesting results.

Whether there is any variable that can predict maintenance of LVEF after initial response to BB therapy in patients with HF remains to be discovered. Our study showed that age and NYHA class were important predictors of LVEF response compared with other predictors such as BB dose. These results are consistent with prior studies that have shown that age and NYHA class have a strong association with LVEF response to BBs [14, 22]. Regarding dosing of BBs, in the multicenter oral carvedilol heart failure assessment (MOCHA) trial, carvedilol (12.5–50 mg/day) generated dose-related LVEF improvement (5–8%) in HF patients, of whom 77% were Caucasians [7]. The carvedilol dose in our patients was about the same dose as that used in the MOCHA trial, but the magnitude of the LVEF improvement for Caucasians in our study was higher. Although this finding is consistent with other studies [10, 42, 43], to the best of our knowledge there are no prior studies regarding BB dosing and LVEF response in Hispanics. In our study, we also confirmed the finding that the effect of BBs on LVEF response was similar irrespective of type of BB used (metoprolol or carvedilol) [10, 42, 43]. Therefore, Hispanics with NICM may have worse post-response LVEF decline irrespective of BB dose and type of BB used compared with other races. Given that prior data have shown differences in LVEF response to BBs [15, 29–32, 40, 41] due to genetic differences (B-gene polymorphisms), genetic background might explain variation in post-response LVEF decline [15].

Finally, baseline LVEF was an important predictor of post-response LVEF decline. Our data is consistent with prior studies that have shown that baseline LVEF has a significant association with response to BB therapy [9, 10]. The increase in LVEF is greater in patients with lower baseline LVEF after treatment with BB therapy [9]. The down-regulation of beta-1-receptor density may be greater with higher chronic catecholamine exposure, which may be the case with more severe cardiomyopathy [10]. BB therapy may then up-regulate beta-1-receptor density to a greater extent in these more severe disease states.

Due to the retrospective nature of the study, expected limitations were encountered. The number of patients enrolled in this study precluded restriction of analyses to only those with low ejection fraction or only those with symptoms of HF. Those variables that were determined by self-report or review of the medical records are beyond the control of the investigators and, thus, subject to error. There was also a lack of availability of data on medical therapy and a lack of information regarding socioeconomic status, including education and income, that may have had an effect on HF outcomes. In addition, this is a single-center study and the findings may not confer external validity. In our Hispanic population, we did not identify special subgroups such as Mexican-origin Hispanics versus those of Caribbean-origin, subgroups which have been shown to have differences in LV remodeling parameters [34, 35]. Finally, the methods used in this study serve only to describe statistical associations between variables, which are not necessarily proof of causation.

5 Conclusion

A significant proportion (13.44%) of NICM patients who experienced an improvement in LVEF with BB therapy in the first year had a subsequent decline. Race, NYHA class, baseline LVEF, and age are important predictors of post-response LVEF decline. An underlying genetic difference may explain differences in LVEF response to BB therapy observed in this study. Future studies should evaluate genetic polymorphisms affecting beta-adrenoceptor function in patients with NICM.

Acknowledgments Dr. Kelesidis contributed to collecting the data, quantitation of echocardiograms, data analysis, and writing and editing the manuscript. Dr. Hourani contributed to collecting the data, writing and editing the manuscript. Dr. Varughese contributed to collecting the data, writing and editing the manuscript. Dr. Zolty contributed to conceiving the study, quantitation of echocardiograms, data analysis, and writing and editing the manuscript.

Disclosure statement Funding for this project was provided by the Congestive Heart Failure Division Fund, Montefiore Medical Center. These data were presented in part at the 13th Annual Scientific meeting of the Heart Failure Society of America, September 2009, Boston, MA, USA. None of the authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
References

1. Gillum RF. The epidemiology of cardiovascular disease in black Americans. N Engl J Med. 1996;335:1597–9.
2. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609–16.
3. Aronow WS, Ahn C, Kronzon I. Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites. Am J Cardiol. 1999:84(611–2):A9.
4. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A–13A.
5. Morales LS, Lara M, Kington RS, Valdez RO, Escare J. Socioeconomic, cultural, and behavioral factors affecting Hispanic health outcomes. J Health Care Poor Underserved. 2002;13:477–503.
6. Bristow MR, O’Connell JB, Gilbert EM, French WJ, Leatherman G, Kantowitz NE, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 1994;89:1632–42.
7. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807–16.
8. Lowes BD, Gill EA, Abraham WT, Larрин JR, Robertson AD, Bristow MR, et al. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999;83:1201–5.
9. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A study of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–9.
10. Gilbert EM, Abraham WT, Olsen S, Hattert B, White M, Mealy P, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996;94:2817–25.
11. Morimoto S, Shimizu K, Yamada K, Hiramitsu S, Hishida H. Can beta-blocker therapy be withdrawn from patients with dilated cardiomyopathy? Am Heart J. 1999;138:456–9.
12. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in the outcome of left ventricular systolic dysfunction. Am J Card Fail. 2000;6:183–6.
13. Thomas KL, East MA, Velazquez EJ, Tuttle RH, Shaw LK, O’Connor CM, et al. Outcomes by race and etiology of patients with left ventricular systolic dysfunction. Am J Cardiol. 2005;96:956–63.
14. Liggett SB, Miale-Perez J, Thaneeen-Chen S, Weber SA, Greene SM, Hodne D, et al. Polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103:11288–93.
15. Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001;344:1358–65.
16. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55.
17. Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8.
18. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7.
19. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659–67.
20. Davidson JA, Kannel WB, Lopez-Candales A, Morales L, Moreno PR, Ovalle F, et al. Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action. Ethn Dis. 2007;17:568–73.
21. Brophy JM, Joseph L, Routlev JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001;134:550–60.
22. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, et al. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation. 1990;82:473–83.
23. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Yansowitz FG, O’Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy; assessment of the left ventricular ejection fraction using dobutamine stress cardiovascular magnetic resonance. Heart. 2005;91:1471–2.
24. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei CL. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J. 2003;145:292–9.
25. de Groot P, Delour P, Mouquet F, Lamblin N, Dagorn J, Hennebert O, et al. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J. 2007;154:889–95.
26. Boucher M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899–907.
27. Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev. 2010;15:187–96.
28. Miale PJ, Rathz DA, Petroshievskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003:9:1300–5.
29. Terra SG, Hamilton KK, Paul DF, Lee CR, Patterson JH, Adams KP, et al. Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics. 2005;15:227–34.
30. Magnusson Y, Levin MC, Eggertsen R, Nyström E, Mobini R, Schaufelberger M, et al. Ser49Gly of beta 1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clin Pharmacol Ther. 2005;78:221–31.
31. Hunt KJ, Resendiz RG, Williams K, Haffner SM, Stern MP, Hazuda HP. All-cause and cardiovascular mortality among Mexican-American and non-Hispanic White older participants in the San Antonio Heart Study—evidence against the “Hispanic paradox”. Am J Epidemiol. 2003;158:1048–57.
34. Bild DE, Detrano R, Peterson D, Guerci A, Liu K, Shahar E, et al. Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005;111:1313–20.
35. Rodriguez CJ, Diez-Roux AV, Moran A, Jin Z, Kronmal RA, Lima J, et al. Left ventricular mass and ventricular remodeling among Hispanic subgroups compared with non-Hispanic blacks and whites: MESA (Multi-ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2010;55:234–42.
36. Allison MA, Budoff MJ, Wong ND, Blumenthal RS, Schreiner PJ, Criqui MH. Prevalence of and risk factors for subclinical cardiovascular disease in selected US Hispanic ethnic groups: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2008;167:962–9.
37. Gonzalez BE, Borrell LN, Choudhry S, Naqvi M, Tsai HJ, Rodriguez-Santana JR, et al. Latino populations: a unique opportunity for the study of race, genetics, and social environment in epidemiological research. Am J Public Health. 2005;95:2161–8.
38. Flegal KM, Ezzati TM, Harris MI, Haynes SG, Juarez RZ, Knowler WC, et al. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey, 1982–1984. Diabetes Care. 1991;14:628–38.
39. Troncoso R, Moraga F, Chiong M, Roldan J, Bravo R, Valenzuela R, et al. Gln(27)–>Glu beta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Pharmacol Toxicol. 2009;104:374–8.
40. Eichhorn EJ, Bristow MR. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med. 2001;2:20–3.
41. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol. 2003;41:1529–38.
42. Metra M, Giubini R, Nodari S, Boldi E, Modena MG, Dei CL. Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546–51.
43. Sanderson JE, Chan SK, Yip G, Yeung LY, Chan KW, Raymond K, et al. Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol. 1999;34:1522–8.